Day: March 23, 2022

First Watch Restaurant Group, Inc. Reports Strong 2021 Financial Results and Provides 2022 Outlook

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

Total revenues of $601.2 million and system-wide sales of $750.7 million 31 system-wide restaurants opened in 12 states Q4 2021 same-restaurant sales growth of 36.7% vs. Q4 2020 and 20.6% vs. Q4 2019 Q4 2021 same-restaurant traffic growth of 31.9% vs. Q4 2020 and 6.1% vs. Q4 2019BRADENTON, Fla., March 23, 2022 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG), (“First Watch” or the “Company”) the Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended December 26, 2021 (“Q4 2021”) and fiscal year ended December 26, 2021 (“2021”) compared to thirteen weeks ended December 27, 2020 (“Q4 2020”) and fiscal year ended December 27, 2020 (“2020”) and provided an outlook for the fiscal year ending December 25, 2022 (“2022”). “I am proud to share our...

Agrify Announces Record Fourth Quarter and Fiscal Year 2021 Results

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

2021 Revenue Increased 395% Year-Over-Year to $59.9 Million Fourth Quarter Revenue Increased 481% Year-Over-Year to $25.3 Million BILLERICA, Mass., March 23, 2022 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), the most innovative provider of advanced cultivation and extraction solutions for the cannabis industry, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021. “During 2021, we drove significant year-over-year growth, launched our Total Turn-Key Solution for cannabis cultivators, created a significant backlog of future high-margin recurring revenues, drove tremendous pipeline velocity, implemented innovative technological advancements to our Vertical Farming Unit, and established ourselves as the leader in premium extraction solutions through a series...

EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

First regulatory submissions for lead oncology programs aumolertinib and sugemalimab are expected to be ex-U.S. in 2H 2022; continuing to engage in discussions with the FDA Continue expanding the Global Buyers Club; goal is to have MOUs in place with payers and health systems that cover approximately 350 million lives by the end of 2022 Strong cash position with expected runway into 2025; $1.7 billion in cash and cash equivalents as of December 31, 2021 EQRx to host conference call and webcast today at 8:00 a.m. ETCAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today reported financial results for the quarter and full year ended December 31, 2021 and provided an...

Immatics Announces Full Year 2021 Financial Results and Corporate Update

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation Multiple IMA203 Phase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level, checkpoint combination therapy, and 2nd-generation approach IMA203CD8 Immatics entered a global licensing agreement with Bristol Myers Squibb to collaborate on clinical development of TCR Bispecific (TCER®) IMA401 targeting MAGEA4/A8; agreement includes $150million upfront payment, up to $770 million in milestone payments, tiered double-digit royalties and a co-promotion option in the U.S. TCER®IMA401 IND1approved by regulatory authorities in February 2022; initiation of patient treatment in the first half of 2022 TCER® IMA402 targeting PRAME demonstrated preclinical...

VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023Completed patient enrollment in the 409 patient OVAL Phase 3 registration enabling trial investigating ofra-vec in patients with platinum-resistant ovarian cancerPreliminary data from ofra-vec Phase 2 trials in mCRC and rGBM expected in 2022VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders, expected to enter the clinic in 2H 2022KOL event in NYC to discuss ofra-vec in ovarian cancer planned for April 11, 2022Conference Call and Webcast at 8:30 a.m. EDT TodayTEL AVIV, Israel and NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical...

Aspira Women’s Health Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

Total Revenue Increased 46% to $6.8 million; OVA1 Volume Grew 28% to 17,359 Units Exercise of option in the Harvard Dana-Farber Cancer Institute Collaboration Leadership and Board appointments implemented in First Quarter of 2022 Conference Call and Webcast scheduled for today, March 23rd at 8:30 a.m. ET AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2021. “We are pleased to announce our full 2021 results and early 2022 trends. The trend in new ordering physicians as we enter the new year is extremely encouraging,” noted Valerie Palmieri, Aspira’s Executive Chair. “We are excited about the success of our collaboration...

First Advantage Delivers Record Fourth Quarter and Full Year Financial Results

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

Reports Sixth Consecutive Quarter of Double-Digit Revenue Growth Fourth Quarter 2021 Financial Highlights(All results compared to prior year period)Revenues were $212.5 million, an increase of 35.8%, compared to $156.5 million in the prior year period Net income was $15.4 million, compared to a net loss of $(5.9) million in the prior year period Adjusted EBITDA1 was $69.4 million, compared to $44.6 million in the prior year period Adjusted Net Income1 was $46.5 million, compared to $24.7 million in the prior year periodFull Year 2021 Financial Highlights(All results compared to prior year periods; Successor period is defined as the period from February 1, 2020 through December 31, 2020; Predecessor period is defined as the period from January 1, 2020 through January 31, 2020)Revenues were $712.3 million, compared to $472.4 million...

Magnetic Resonance Imaging Equipment Market Size [2022-2029] worth USD 11.03 Billion | exhibiting a CAGR of 6.5%

Written by Customer Service on March 23, 2022. Posted in Mergers And Acquisitions.

The “magnetic resonance imaging equipment market” size was USD 6.71 billion in 2021. The market is projected to grow from USD 7.12 billion in 2022 to USD 11.03 billion in 2029 at a CAGR of 6.5% during the 2022-2029 period. Pune, India, March 23, 2022 (GLOBE NEWSWIRE) — The “magnetic resonance imaging equipment market” size was USD 6.71 billion in 2021. The market is projected to grow from USD 7.12 billion in 2022 to USD 11.03 billion in 2029 at a CAGR of 6.5% during the 2022-2029 period. This vital information is presented by Fortune Business Insights™, in its report, titled, “Magnetic Resonance Imaging Equipment Market, 2022-2029.” Factors such as the ability to diagnose, treat, & manage a variety of critical disorders along with the procedure being completely non-invasive will increase the footprint of the market during...

India Plasma Fractionation Market Size [2022-2030] worth USD 470.6 Million | exhibiting a CAGR of 4.2%

Written by Customer Service on March 23, 2022. Posted in Mergers And Acquisitions.

Key Prominent Players Covered in the India Plasma Fractionation Market are PlasmaGen BioSciences Pvt. Ltd. (Bangalore, India), Reliance Life Sciences (Mumbai, India), Biocon Limited (Bangalore, India), Intas Pharmaceuticals Ltd. (Ahmedabad, India), Bharat Serums and Vaccines Limited (BSV) (Mumbai, India), VIRCHOW BIOTECH (Hyderabad, India), Fusion Healthcare (Hyderabad, India), Kedrion S.p.A (Barga, Italy), Hemarus (Hyderabad, India) Pune, India, March 23, 2022 (GLOBE NEWSWIRE) — The India plasma fractionation market size is anticipated to hit USD 470.6 million by 2030 and exhibit a CAGR of 4.2% during the forecast period. The growing prevalence of immune-deficiency disorders and the expanding geriatric population are expected to be the key factors driving the market growth. Fortune Business InsightsTM has presented this information...

Wound Care Market Size [2022-2029] Worth USD 28.23 Billion | Exhibit a CAGR 6.2%

Written by Customer Service on March 23, 2022. Posted in Mergers And Acquisitions.

Wound Care Market Size to Hit USD 28.23 billion, at CAGR of 6.2% by 2028; Technological Advancements Remain Prominent for Stakeholders Pune, India, March 23, 2022 (GLOBE NEWSWIRE) — The global wound care market size was valued at USD 17.49 billion in 2021. The market is projected to rise from USD 18.51 billion in 2022 to USD 28.23 billion by 2029 at a 6.2% CAGR during the forecast period. Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled, “Wound Care Market, 2022-2029.” According to an analysis, the launch of sophisticated products and a surge in the number of patients with chronic wounds have augured well for the industry outlook. Leading companies are likely to expand their penetration amidst rising cases of diabetic foot ulcers and pressure ulcers.Request a Sample: https://www.fortunebusinessinsights.com/enquiry/sample/wound-care-market-103268COVID-19...

Day: March 23, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals